Bone Cancer



Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study.


Condition:   Osteosarcoma, Advanced
Intervention:   Drug: Apatinib
Sponsors:   Henan Cancer Hospital;   Jiangsu HengRui Medicine Co., Ltd.
Recruiting - verified May 2017


Phase I Clinical Trial of GRID Therapy in Pediatric Osteosarcoma of the Extremity


Conditions:   Osteosarcoma in Children;   Radiation Toxicity
Intervention:   Radiation: GRID radiotherapy
Sponsor:   University of Arkansas
Not yet recruiting - verified May 2017


Clinical Trial Evaluating Metronomic Chemotherapy in Patients With Metastatic Osteosarcoma


Condition:   Osteosarcoma
Interventions:   Drug: Cyclophosphamide;   Drug: Methotrexate
Sponsor:   Grupo de Apoio ao Adolescente e a Crianca com Cancer
Recruiting - verified March 2017


A Study of Pembrolizumab in Patients With Relapsed Or Metastatic Osteosarcoma Not Eligible for Curative Surgery


Condition:   Osteosarcoma
Intervention:   Drug: Pembrolizumab
Sponsors:   Oslo University Hospital;   Italian Sarcoma Group;   Merck Sharp & Dohme Corp.
Not yet recruiting - verified January 2017


A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma


Condition:   Osteosarcoma
Interventions:   Drug: Avelumab;   Other: Questionnaires
Sponsors:   St. Jude Children's Research Hospital;   National Cancer Institute (NCI)
Recruiting - verified May 2017


The Application of Personalized Titanium Plate in the Bone Tumors Around the Knee


Condition:   Bone Tumors
Intervention:   Procedure: Personalized titanium plate
Sponsors:   Guangzhou General Hospital of Guangzhou Military Command;   Medical Center of Assessment, Prevention and Treatment of Bone & Joint Diseases, Guangdong, China;   The First Affiliated Hospital of Guangzhou Medical University
Completed - verified February 2017


Pre-Surgical Supervised Exercise for Bone Cancer Patients


Condition:   Malignant Neoplasms of Bone and Articular Cartilage
Intervention:   Behavioral: Supervised Exercise Program
Sponsor:   M.D. Anderson Cancer Center
Recruiting - verified May 2017


Phase II Protocol Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone


Condition:   Bone Cancer
Interventions:   Drug: Stereotactic Body Radiation Therapy (SBRT);   Device: Stereotactic Linear Accelerator
Sponsor:   Dana-Farber Cancer Institute
Not yet recruiting - verified August 2016


Phase II Trial for the Treatment of Relapsed Osteosarcoma


Condition:   OSTEOSARCOMA
Interventions:   Drug: Gemcitabine and Docetaxel;   Drug: Ifosfamide
Sponsor:   Italian Sarcoma Group
Recruiting - verified March 2017


Cost-effectiveness Evaluation of the Use of a Patient Specific Instrument for Surgical Resection of Malignant Bone Tumor Within the Pelvis Versus the Conventional Surgical Treatment


Condition:   Sarcoma, Bone Tumor
Interventions:   Device: Patient specific instrument;   Procedure: Conventional surgical treatment
Sponsor:   Nantes University Hospital
Recruiting - verified August 2016


Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma


Condition:   Recurrent Osteosarcoma
Interventions:   Biological: humanized anti-GD2 antibody;   Drug: GM-CSF
Sponsors:   Memorial Sloan Kettering Cancer Center;   Children's Hospital Los Angeles;   M.D. Anderson Cancer Center
Recruiting - verified September 2016


Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma


Condition:   Recurrent Osteosarcoma
Interventions:   Drug: Glembatumumab Vedotin;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting - verified May 2017


Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma


Conditions:   Childhood Osteosarcoma;   Metastatic Osteosarcoma;   Recurrent Osteosarcoma
Interventions:   Biological: Denosumab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified July 2016


A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS)


Condition:   Osteosarcoma
Interventions:   Drug: Mifamurtide;   Drug: Ifosfamide
Sponsors:   University of Oxford;   Millennium: The Takeda Oncology Company;   National Institute for Health Research, United Kingdom;   Oxford University Hospitals NHS Trust;   European Commission
Completed - verified March 2017


A Retrospective Non-intervention Study to Characterize FOlate Rescue Treatment in Osteosarcoma Patients Treated With HDMTX


Condition:   Osteosarcoma
Intervention:   Drug: Methotrexate
Sponsor:   Isofol Medical AB
Completed - verified September 2016


Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma


Condition:   Metastatic Osteosarcoma
Interventions:   Drug: Sm-EDTMP;   Other: Autologous Stem Cell Infusion;   Radiation: External Beam Radiotherapy
Sponsor:   Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified March 2017


Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung


Conditions:   Osteosarcoma;   Metastatic Osteosarcoma
Intervention:   Drug: pazopanib
Sponsors:   Vector Oncology;   GlaxoSmithKline
Active, not recruiting - verified January 2017


Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma


Condition:   Osteosarcoma
Interventions:   Drug: Lithium Carbonate;   Drug: Placebo
Sponsors:   Sun Yat-sen University;   Qilu Hospital of Shandong University;   Nanfang Hospital of Southern Medical University;   Shenzhen Second People's Hospital;   Guangdong Provincial Hospital of Traditional Chinese Medicine;   Shanghai 6th People's Hospital
Recruiting - verified October 2016


ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma


Condition:   Osteosarcoma
Interventions:   Drug: Mifamurtide arm;   Other: 3 drugs arm
Sponsor:   Italian Sarcoma Group
Recruiting - verified March 2017


Surveillance Study of Patients With Newly Diagnosed Osteosarcoma


Condition:   Osteosarcoma
Intervention:   Drug: Mifamurtide
Sponsor:   Millennium Pharmaceuticals, Inc.
Terminated - verified January 2017


Outpatient Administration of High Dose Methotrexate (HD MTX) in Patients With Osteosarcoma


Condition:   Osteosarcoma
Intervention:   Drug: High Dose Methotrexate
Sponsor:   The Hospital for Sick Children
Completed - verified April 2017


Adjuvant High-Dose Thiotepa and Stem Cell Rescue Associated With Conventional Chemotherapy in Relapsed Osteosarcoma


Condition:   Osteosarcoma
Intervention:   Drug: Thiotepa
Sponsor:   Centre Leon Berard
Active, not recruiting - verified December 2016


A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung


Condition:   Osteosarcoma
Interventions:   Drug: Saracatinib;   Drug: Placebo
Sponsors:   Sarcoma Alliance for Research through Collaboration;   AstraZeneca
Active, not recruiting - verified March 2017


DVT Prophylaxis in Orthopaedic Oncology Patients - A Safety Study


Condition:   Bone Cancer
Intervention:   Drug: Dalteparin
Sponsors:   M.D. Anderson Cancer Center;   Pfizer
Active, not recruiting - verified September 2016


Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma


Conditions:   Localized Osteosarcoma;   Metastatic Osteosarcoma
Interventions:   Drug: doxorubicin hydrochloride;   Drug: cisplatin;   Drug: methotrexate;   Procedure: therapeutic conventional surgery;   Biological: peginterferon alfa-2b;   Drug: ifosfamide;   Drug: etoposide;   Procedure: quality-of-life assessment;   Other: questionnaire administration
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI);   University College London Hospitals
Active, not recruiting - verified May 2017

Refine Your Search Advanced Search